Philips Secures FDA Clearance for Elevate Plus AI Ultrasound Upgrade

Why It Matters

The clearance enables Philips to roll out AI‑powered ultrasound automation across two major markets, helping hospitals lower operator variability, speed diagnoses, and meet rising imaging demand.

Key Takeaways

• Philips cleared Elevate Plus AI upgrade in US and Europe
• AI Auto Measure Abdomen achieves >93% accuracy versus experts
• Koios AI now classifies breast and thyroid lesions on‑cart
• Imaging tools XRes Pro+ and Super Res MVI Pro enhance detail
• Upgrade targets workflow automation, reducing repeat scans

Pulse Analysis

Securing both FDA 510(k) clearance and the European CE mark positions Philips to commercialize Elevate Plus in the United States and the EU, the two largest markets for diagnostic imaging equipment. The dual approval not only validates the safety and efficacy of the AI‑enhanced software but also accelerates Philips’ product roadmap, allowing it to bundle the upgrade with its existing EPIQ Elite and Affiniti ultrasound systems. For a company that reported €5 billion in imaging revenue last year, expanding a high‑margin software layer can boost recurring revenue and strengthen its competitive foothold against rivals such as GE Healthcare and Siemens Healthineers.

Elevate Plus introduces AI modules that automate routine measurements and provide real‑time decision support. The Auto Measure Abdomen tool claims more than 93 % concordance with specialist readings, cutting the time clinicians spend on manual calipers and reducing inter‑operator variance. Meanwhile, Koios AI brings on‑cart breast‑lesion (Bi‑RADS) and thyroid‑nodule (Ti‑RADS) classification, eliminating the need for separate workstations and streamlining reporting. Combined with imaging refinements like XRes Pro+ and Super Res MVI Pro, the platform promises sharper tissue contrast and clearer microvascular flow, which can translate into faster, more confident diagnoses in busy emergency departments and outpatient clinics.

The rollout of Elevate Plus reflects a broader shift toward software‑first strategies in medical imaging, where manufacturers monetize AI algorithms as add‑on upgrades rather than selling entirely new hardware. Hospitals that adopt the upgrade may see reduced repeat scans, lower staffing costs, and higher throughput, all of which are critical as imaging demand outpaces capacity. However, integration challenges, data privacy concerns, and the need for clinician training could temper adoption speed. If Philips can demonstrate tangible workflow savings, the move could set a new benchmark for AI‑enabled ultrasound and spur further investment across the sector.